Improving access to medicines for millions of patients worldwide. We do this by providing affordable, innovative, and high-quality solutions.
Founded in 1974 by Dr. Barry Sherman, we’re a proudly Canadian, global pharmaceutical company that produces high-quality, affordable medicines (both generic and innovative pharmaceuticals) for patients around the world.
From its humble origins of only two employees, we’ve grown to employ more than 11,000 people worldwide in manufacturing, R&D and commercial operations. Through vertical integration, the Apotex Group of Companies is comprised of Apotex Generics, Apotex Active Pharmaceutical Ingredients, Apobiologix and ApoPharma (innovative products).
We export to more than 115 countries and territories, and operate in more than 45 countries, including a significant presence in the US, Mexico and India where we continue to invest. Our footprint includes an expanding network of Affiliates and Distributors, as well as joint ventures and strategic alliances.
Globally, we produce approximately 25 billion doses per year, which, in turn are used to fill approximately 90 million prescriptions in Canada alone, or one in five prescriptions.
In the past five years alone, we have helped to bring more than 20 prescription drugs to market before patent expiry, and in doing so, saved public and private payers more than $4 billion. In total, we have saved Canadians almost $19 billion by bringing products to market early.
We are the single largest investor in research and development of any pharmaceutical company in Canada – brand or generic. We have the largest labs in the Canadian pharmaceutical industry and more than 1100 active R&D projects representing more than 500 molecules in 50 countries. In the past 10 years, we have invested $1 billion in research and development, with an additional $2 billion planned for the next 10 years.